Glycemic Control With Insulin Glargine Plus Insulin Glulisine Versus Premixed Insulin Analogues in Real-World Practices: A Cost-Effectiveness Study With a Randomized Pragmatic Trial Design (Q48637978)

From Wikidata

Jump to navigation Jump to search

scientific article published on June 30, 2011

Language	Label	Description	Also known as
English	Glycemic Control With Insulin Glargine Plus Insulin Glulisine Versus Premixed Insulin Analogues in Real-World Practices: A Cost-Effectiveness Study With a Randomized Pragmatic Trial Design	scientific article published on June 30, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21719107

Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21719107

Glycemic Control With Insulin Glargine Plus Insulin Glulisine Versus Premixed Insulin Analogues in Real-World Practices: A Cost-Effectiveness Study With a Randomized Pragmatic Trial Design (English)

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

1 reference

based on heuristic

inferred from title

insulin glargine

1 reference

based on heuristic

inferred from title

author name string

Quanwu Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21719107

Madhu Bhushan

6

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21719107

Rajat Bhushan

7

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21719107

Philip A. Levin

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21719107

6 December 2024

James H. Mersey

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21719107

6 December 2024

Francis Y. Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21719107

6 December 2024

Lee A. Bromberger

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21719107

6 December 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21719107

6 December 2024

publication date

30 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21719107

full work available at URL

https://api.elsevier.com/content/article/PII:S0149291811003924?httpAccept=text/xml

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

https://api.elsevier.com/content/article/PII:S0149291811003924?httpAccept=text/plain

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Clinical Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21719107

33

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21719107

7

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21719107

841-850

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21719107

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

1

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial

2

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs

3

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US

4

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes

5

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison

6

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

The effectiveness of insulin initiation regimens in patients with type 2 diabetes mellitus: a large national medical records review study comparing a basal insulin analogue to premixed insulin

7

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Mealtime 50/50 basal prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week

8

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naive Japanese patients with diabetes

9

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Insulin therapy for type 2 diabetes: premixed or basal-prandial?

10

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study

11

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study.

12

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials

13

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: The Canadian INSIGHT Study

14

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients

15

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity

16

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Pragmatic clinical trials

17

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

The gap between clinical trials and clinical practice: the use of pragmatic clinical trials to inform regulatory decision making

18

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers

19

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

A new 'Mechanistic-Practical” Framework for designing and interpreting randomized trials

20

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Why we will remain pragmatists: four problems with the impractical mechanistic framework and a better solution

21

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Explanatory and pragmatic attitudes in therapeutical trials

22

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Pragmatic Trials — Guides to Better Patient Care?

23

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Reliability and Validity of a Diabetes Quality-of-Life Measure for the Diabetes Control and Complications Trial (DCCT)

24

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

EuroQol--a new facility for the measurement of health-related quality of life

25

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

The validity and reproducibility of a work productivity and activity impairment instrument

26

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Patient-assessed health outcome measures for diabetes: a structured review

27

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Cost-effectiveness of insulin analogues for diabetes mellitus

29

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

When basal insulin therapy in type 2 diabetes mellitus is not enough--what next?

30

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

31

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

33

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).

34

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

35

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine

36

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs

37

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Analysis of cost and utilization of health care services before and after initiation of insulin therapy in patients with type 2 diabetes mellitus

38

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis

39

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes

40

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products

41

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products

42

1 reference

10.1016/J.CLINTHERA.2011.05.091

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.05.091

6 December 2024

Identifiers

10.1016/J.CLINTHERA.2011.05.091

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21719107

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21719107

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48637978&oldid=2283932971"